Critical questions in development of targeted nanoparticle therapeutics - Test2 - elhamkhani - TriplyDB

Critical questions in development of targeted nanoparticle therapeutics

Critical questions in development of targeted nanoparticle therapeutics

http://www.wikidata.org/entity/Q26751896

about

sameAs

Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies.Recent developments in nanomedicine for melanoma treatment.Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.The Targeted Antitumor Effects of C- PC/CMC-CD59sp Nanoparticles on HeLa Cells in Vitro and in Vivo.Dendrimers for Ocular Drug Delivery.Multimodal imaging of the receptor for advanced glycation end-products with molecularly targeted nanoparticles Make It Simple: (SR-A1+TLR7) Macrophage Targeted NANOarchaeosomes

P2860

Q38658279-63295D80-F078-4682-8338-1D1BCD737700 Q38740124-83A2CDF9-1A4E-4A49-9A7E-9C9F8BB45292 Q38978632-DE67D9F6-6B66-4620-93F3-22A41980F65E Q41721656-E7CC93F4-117D-465F-8E2A-5D2DFCD9C0A8 Q45073183-DCFF1F47-8214-496D-B1B0-AE4581CB2FDA Q59133666-C10F430E-589D-4540-A705-6B3309485262 Q59136461-73D8AFAE-F193-4D62-8D08-CFEFA2C6E958

P2860

Critical questions in development of targeted nanoparticle therapeutics

http://www.wikidata.org/entity/Q26751896

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Critical questions in development of targeted nanoparticle therapeutics

@ast

Critical questions in development of targeted nanoparticle therapeutics

@en

Critical questions in development of targeted nanoparticle therapeutics

@nl

type

label

Critical questions in development of targeted nanoparticle therapeutics

@ast

Critical questions in development of targeted nanoparticle therapeutics

@en

Critical questions in development of targeted nanoparticle therapeutics

@nl

prefLabel

Critical questions in development of targeted nanoparticle therapeutics

@ast

Critical questions in development of targeted nanoparticle therapeutics

@en

Critical questions in development of targeted nanoparticle therapeutics

@nl

P1433

Q26751896-F9AA0C9D-1A13-48D8-9A7D-8D9FBB03F49B

P1476

Q26751896-0DC06523-0E78-4E1B-89C7-EFC9D2BC8923

P2093

Q26751896-8E0EE51C-0D9F-4E29-B455-0E92917E29A7

P2860

Q26751896-064B0CCB-B9AF-4294-8891-F18A53937CE1

Q26751896-0F8840FF-593F-497B-AB21-81F36050CD6D

Q26751896-11878FCE-35BD-41D1-A0C3-C940C99ABF04

Q26751896-394B9D0C-D3FD-42A5-98FD-0ACC9BA74C6E

Q26751896-3964A832-D0C4-46D9-B269-D2975653BB21

Q26751896-3E88194F-7108-4B84-9C2E-0C3289631DEF

Q26751896-4522FD9E-B44F-447C-B83A-F75191D6A232

Q26751896-4B3B1387-53E1-4A14-907E-196F8A1D491E

Q26751896-4FB84636-656D-4DF8-BB16-01CF890FE61A

Q26751896-6B5534B4-B2FB-40E2-B2B6-D29B1A352DF1

P304

Q26751896-4092DD35-7D72-4E40-A9BC-73785A2F000F

P31

Q26751896-EB85085E-3B87-47E0-A775-DF9FE45D684B

P3181

Q26751896-67018E22-A499-4069-A26A-D07F8B53B9B2

P356

Q26751896-49A4DBC4-1F94-4A91-8BAC-61ED81269017

P407

Q26751896-ACF7D7C8-FB60-4E91-818F-4BF82527442B

P433

Q26751896-159CB0DD-B8E0-4F0B-BFC5-D2B349DB95BD

P478

Q26751896-21BA5D73-FE7D-40E6-8279-40B87A7B808D

P577

Q26751896-D7F600C3-9453-4D47-9ED2-8A109829BAE6

P5875

Q26751896-D19AE957-A1B5-4936-8ADD-A1A71EC04842

P698

Q26751896-58CCB34D-5383-4470-A802-6FBE84A98F31

P921

Q26751896-E0AA9D42-103B-438B-843C-FB5B3062D174

P932

Q26751896-964C39C4-F3D1-4533-B19D-94A25BBD03AF

P3181

P356

P1433

Regenerative biomaterials

P1476

Critical questions in development of targeted nanoparticle therapeutics

@en

P2093

Richard Korsmeyer

http://www.w3.org/2001/XMLSchema#string

P2860

Current understanding of interactions between nanoparticles and the immune system

Overview about the localization of nanoparticles in tissue and cellular context by different imaging techniques

The big picture on nanomedicine: the state of investigational and approved nanomedicine products

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy

Inhibition of phosphoinositol 3 kinase contributes to nanoparticle-mediated exaggeration of endotoxin-induced leukocyte procoagulant activity

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Drug-like properties and the causes of poor solubility and poor permeability.

Targeting kidney mesangium by nanoparticles of defined size.

Cancer nanomedicines: so many papers and so few drugs!

P304

143-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5121499

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/RB/RBW011

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

299344788

http://www.w3.org/2001/XMLSchema#string

P698

27047683

http://www.w3.org/2001/XMLSchema#string

P921

P932

4817320

http://www.w3.org/2001/XMLSchema#string